These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 18413519)

  • 1. Prevention of exuberant granulation tissue and neovascularization in the rat cornea by naltrexone.
    Zagon IS; Klocek MS; Griffith JW; Sassani JW; Komáromy AM; McLaughlin PJ
    Arch Ophthalmol; 2008 Apr; 126(4):501-6. PubMed ID: 18413519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naltrexone and insulin are independently effective but not additive in accelerating corneal epithelial healing in type I diabetic rats.
    Klocek MS; Sassani JW; McLaughlin PJ; Zagon IS
    Exp Eye Res; 2009 Nov; 89(5):686-92. PubMed ID: 19576213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dry eye reversal and corneal sensation restoration with topical naltrexone in diabetes mellitus.
    Zagon IS; Klocek MS; Sassani JW; McLaughlin PJ
    Arch Ophthalmol; 2009 Nov; 127(11):1468-73. PubMed ID: 19901212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topically applied naltrexone restores corneal reepithelialization in diabetic rats.
    Klocek MS; Sassani JW; McLaughlin PJ; Zagon IS
    J Ocul Pharmacol Ther; 2007 Apr; 23(2):89-102. PubMed ID: 17444796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocular surface abnormalities related to type 2 diabetes are reversed by the opioid antagonist naltrexone.
    Zagon IS; Sassani JW; Immonen JA; McLaughlin PJ
    Clin Exp Ophthalmol; 2014 Mar; 42(2):159-68. PubMed ID: 23777539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naltrexone, an opioid antagonist, facilitates reepithelialization of the cornea in diabetic rat.
    Zagon IS; Jenkins JB; Sassani JW; Wylie JD; Ruth TB; Fry JL; Lang CM; McLaughlin PJ
    Diabetes; 2002 Oct; 51(10):3055-62. PubMed ID: 12351447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Naltrexone accelerates healing without compromise of adhesion complexes in normal and diabetic corneal epithelium.
    Zagon IS; Sassani JW; Myers RL; McLaughlin PJ
    Brain Res Bull; 2007 Apr; 72(1):18-24. PubMed ID: 17303503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical naltrexone accelerates full-thickness wound closure in type 1 diabetic rats by stimulating angiogenesis.
    McLaughlin PJ; Immonen JA; Zagon IS
    Exp Biol Med (Maywood); 2013 Jul; 238(7):733-43. PubMed ID: 23788174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of topical insulin to normalize corneal epithelial healing in diabetes mellitus.
    Zagon IS; Klocek MS; Sassani JW; McLaughlin PJ
    Arch Ophthalmol; 2007 Aug; 125(8):1082-8. PubMed ID: 17698755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topical treatment with the opioid antagonist naltrexone facilitates closure of full-thickness wounds in diabetic rats.
    McLaughlin PJ; Pothering CA; Immonen JA; Zagon IS
    Exp Biol Med (Maywood); 2011 Oct; 236(10):1122-32. PubMed ID: 21917593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical treatment with the opioid antagonist naltrexone accelerates the remodeling phase of full-thickness wound healing in type 1 diabetic rats.
    Immonen JA; Zagon IS; Lewis GS; McLaughlin PJ
    Exp Biol Med (Maywood); 2013 Oct; 238(10):1127-35. PubMed ID: 23986225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adaptation of homeostatic ocular surface epithelium to chronic treatment with the opioid antagonist naltrexone.
    Zagon IS; Sassani JW; McLaughlin PJ
    Cornea; 2006 Aug; 25(7):821-9. PubMed ID: 17068460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Corneal safety of topically applied naltrexone.
    Zagon IS; Klocek MS; Sassani JW; Mauger DT; McLaughlin PJ
    J Ocul Pharmacol Ther; 2006 Oct; 22(5):377-87. PubMed ID: 17076633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical application of naltrexone facilitates reepithelialization of the cornea in diabetic rabbits.
    Zagon IS; Sassani JW; Carroll MA; McLaughlin PJ
    Brain Res Bull; 2010 Feb; 81(2-3):248-55. PubMed ID: 19853024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety profile of topical VEGF neutralization at the cornea.
    Bock F; Onderka J; Rummelt C; Dietrich T; Bachmann B; Kruse FE; Schlötzer-Schrehardt U; Cursiefen C
    Invest Ophthalmol Vis Sci; 2009 May; 50(5):2095-102. PubMed ID: 19151400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bitter Melon Extract Promotes Granulation Tissue Growth and Angiogenesis in the Diabetic Wound.
    Singh R; Garcia-Gomez I; Gudehithlu KP; Singh AK
    Adv Skin Wound Care; 2017 Jan; 30(1):16-26. PubMed ID: 27984270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective blockade of the OGF-OGFr pathway by naltrexone accelerates fibroblast proliferation and wound healing.
    Immonen JA; Zagon IS; McLaughlin PJ
    Exp Biol Med (Maywood); 2014 Oct; 239(10):1300-9. PubMed ID: 25030485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydrogen sulfide accelerates wound healing in diabetic rats.
    Wang G; Li W; Chen Q; Jiang Y; Lu X; Zhao X
    Int J Clin Exp Pathol; 2015; 8(5):5097-104. PubMed ID: 26191204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of topical aflibercept versus topical bevacizumab for the prevention of corneal neovascularization in a rat model.
    Sella R; Gal-Or O; Livny E; Dachbash M; Nisgav Y; Weinberger D; Livnat T; Bahar I
    Exp Eye Res; 2016 May; 146():224-232. PubMed ID: 27020759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of corneal inflammation by the topical use of Ras farnesyltransferase inhibitors: selective inhibition of macrophage localization.
    Sonoda K; Sakamoto T; Yoshikawa H; Ashizuka S; Ohshima Y; Kishihara K; Nomoto K; Ishibashi T; Inomata H
    Invest Ophthalmol Vis Sci; 1998 Nov; 39(12):2245-51. PubMed ID: 9804132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.